Partner With Us NRI

Morepen Laboratories Ltd share Price

Company details

6M Return 38.40%
1Y Return 38.67%
Mkt Cap.(Cr) 1,860.66
Volume 3,692,815
Div Yield 0.00%
OI Chg %
Volume 3,692,815

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Morepen Laboratories announced Q4FY23 results:

  • Company has got three landmark recognitions in last three months including one USFDA approval, one PMDA inspection and one ISO13485 Approval
  • During the current Quarter Q4FY23, the business has stabilised and the consolidated revenues at Rs 367 crore against Rs 372 crore in the same quarter last year.
  • Annual revenues of Rs 1,424 crore have also paced a CAGR of 18% though in the current year revenues of all segments maintained a steady position except Medical Devices.
  • Medical devices business which peaked during covid due to increased demand and inventory buildup has also stabilized in last quarters and is on upward journey. In FY23 the gross revenues at Rs 327 crore were 22% lower than peek of Rs 418 crore in FY22
  • Formulation Business has catching fast and has registered a jump of 28% in this Quarter.
  • Enhanced focus on marketing and advertising activities for better reach and brand recall, has affected the profitability levels.



Result PDF

View Other Company Results


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Morepen Laboratories Ltd Stocks COMPARISION


Equity Capital: 752.91 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 15,612.36 -19,132.24
LAST 3M 53,075.98 -4,241.70
LAST 6M 58,662.39 138,824.89
LAST 12M 133,944.68 162,473.45

Morepen Laboratories Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Morepen Laboratories Limited is an India-based pharmaceutical company. Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin. The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast. It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India. The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally. The company has developed a hi-tech Pharma complex at Morepen Village, Baddi (HP) on 60 acres of land that has various multipurpose pharma facilities for API & finished dosages and a Research Centre. The company was established in the year 1984. The company has filed 14 patents including 6 international PCT applications. The company has filed an international patent on a new amorphous form of the cholesterol-reducing drug Lipitor (Atorvastatin) that is the largest selling drug in the world. During the year 1991-1992, the company set up the new facilities for bulk manufacture of Cephalexin, 7 ADCA and CIMC Chloride at its existing location. During the year 1992-1993, the company started implementing its expansion plans for manufacture Cephalexin, 7ADCA, CIMC Chloride, Research and Development Block and Formulation unit. The company introduced two latest molecules, Ketrolac Tromethamine and Omeprazole. Also, the company also launched Loratadine and Cisapride. During the year 1993-1994, the company increased the installed capacity of Bulk Drugs from 162 MT to 245 MT. The company started the commercial production of Ketorolac Tromethamine, which is a potent analgesic. During the year 1994-1995, the company increased the installed capacity of Drugs & Drug Intermediates from 305 MT to 469 MT. During the year 1995-1996, the company successfully launched high value and high technology products namely, Cisapride & Loratadine. Also, the company launched herbal product namely Paclitaxel, an anti cancer drug. During the year 1996-1997, the company commissioned its own formulation unit, which gave a competitive edge to the company in terms of quality and cost efficiency. During the year 2000-2001, the company increased the installed capacity of Drugs & Drug Intermediates from 916 MT to 1170 MT. The company signed a joint venture with DiaMed AG of Switzerland, a proven international leader in blood group serology diagnostic products. Also, the company developed and launched wide range of contemporary, lifestyle oriented FMHG (Fast Moving Health Goods) Self Medication products. During the year 2001-2002, the company increased the installed capacity of Drugs & Drug Intermediates from 1170 MT to 1251 MT. Also, the company further increased installed capacity of Tablets / Capsules from 25080 Nos to 35000 Nos. During the year 2004-2005, the company developed the new polymorphic from V1 and field patent in 33 countries and in the same year, the company started finalizing marketing partner for filing ANDA`s for the molecule. During the year 2005-2006, the company made 52 DMF filing across ten European countries for six products. Also, the company broadened its offering by introduced new product like Ducal, Rythmix, Montelast, Alcoflam, Levopen, Moezole, and Cefpen-S. During the year 2006-2007, the company improved its presence in the key market of South East Asia, Africa & Australia. During the year, the company acquired more than fifty new prospective customers in Korea, Japan, and Taiwan. During the year, the company started of OTC formulation under the umberalla brand `Dr. Morepen`. During the year 2007-2008, the company made the tie ups with several new business segments. Marketing alliance with World leaders like lmmucor, USA (for immuunohematology system & consumables), Teco Medical Instruments, Germany (for coagulation system & consumables), InTec INC. (for ELISA Kits), Access Bio, USA (for Rapid Malaria Kits), helped the diagnostics division to make deeper inroads into both the consumer market and the blood bank and laboratory segment.

Registered Address

Morepen Village, Nalagarh Road Near Baddi, Solan, Himachal Pradesh, 173205

Tel : 91-01795-276201-03
Email : investors:morepen.com
Website : http://www.morepen.com

Mas Services Limited

AGM Date (Month) : Sep
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 500288
Book Closure Date (Month) :
BSE Group : A
ISIN : INE083A01026

FAQ’s on Morepen Laboratories Ltd Shares

You can buy Morepen Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Morepen Laboratories Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Oct 04, 2023 03:58 PM the closing price of Morepen Laboratories Ltd was ₹ 36.40.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Oct 04, 2023 03:58 PM, the market cap of Morepen Laboratories Ltd stood at ₹ 1,860.66.

The latest PE ratio of Morepen Laboratories Ltd as of Oct 04, 2023 03:58 PM is 39.11

The latest PB ratio of Morepen Laboratories Ltd as of Oct 04, 2023 03:58 PM is 0.40

The 52-week high of Morepen Laboratories Ltd is ₹ 48.45 while the 52-week low is ₹ 24.00

Download Our App

market app
market app